Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine - PubMed (original) (raw)
. 2022 Jan 5;17(1):e0262225.
doi: 10.1371/journal.pone.0262225. eCollection 2022.
Yazdani B Shaik-Dasthagirisaheb 3, Morgan Congdon 4, Rebecca R Young 5, Mohamed Z Patel 6, Tiny Mazhani 6, Sefelani Boiditswe 7, Tirayaone Leburu 7, Kwana Lechiile 7, Tonya Arscott-Mills 4 6 7, Andrew P Steenhoff 4 6 8, Kristen A Feemster 8, Samir S Shah 9, Coleen K Cunningham 10, Stephen I Pelton 3, Matthew S Kelly 2 5
Affiliations
- PMID: 34986196
- PMCID: PMC8730465
- DOI: 10.1371/journal.pone.0262225
Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
Sweta M Patel et al. PLoS One. 2022.
Abstract
Pneumococcal conjugate vaccines reduce the burden of invasive pneumococcal disease, but the sustained effect of these vaccines can be diminished by an increase in disease caused by non-vaccine serotypes. To describe pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine (PCV-13) in July 2012, we performed molecular serotyping of 268 pneumococcal strains isolated from 221 children between 2012 and 2017. The median (interquartile range) age of the children included in this analysis was 6 (3,12) months. Fifty-nine percent of the children had received at least one dose of PCV-13 and 35% were fully vaccinated with PCV-13. While colonization by vaccine serotypes steadily declined following PCV-13 introduction, 25% of strains isolated more than 3 years after vaccine introduction were PCV-13 serotypes. We also observed an increase in colonization by non-vaccine serotypes 21 and 23B, which have been associated with invasive pneumococcal disease and antibiotic resistance in other settings.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Fig 1. Specimen collection and selection for pneumococcal serotyping.
Fig 2. Serotypes of pneumococcal strains isolated from infants and young children in Botswana.
The bars represent the serotypes of identified pneumococcal isolates collected from children in Botswana by year of enrollment. Vaccine serotypes are shaded red to orange, while non-vaccine serotypes are presented in shades of blue. The number of colonizing isolates serotyped is displayed below the enrollment year.
References
- Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16(5):816–23. Epub 2010/04/23. doi: 10.3201/eid1605.091223 ; PubMed Central PMCID: PMC2953990. -DOI -PMC -PubMed
- Botswana: WHO and UNICEF estimates of immunization coverage: 2019 revision. 2019 July 2. Report No.